REFERENCES
- Crom WR, Evans WE. Methotrexate. In: Evans WE, Schentag JJ, Jusko WJ, eds., Applied Pharmacokinetics, Principles of Therapeutic Drug Monitoring. 3d ed. Vancouver: Applied Therapeutics Inc.; 1992. 29-1–29-42.
- Stoller RG Hande KR, Jacobs SA, et al. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med. 1977;297(12):630–634.
- Reiter A Schrappe M, Tiemann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. Blood. 1999;94(10):3294–306.
- Schwartz GJ Muñoz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009;20(3):629–637.
- Xu WQ, Zhang LY, Chen XY, et al. Serum creatinine and creatinine clearance for predicting plasma methotrexate concentrations after high-dose methotrexate chemotherapy for the treatment for childhood lymphoblastic malignancies. Cancer Chemother Pharmacol. 2014;73(1):79–86.
- Joannon P Oviedo I, Campbell M, Tordecilla J. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance. Pediatr Blood Cancer. 2004;43(1):17–22.
- Kerr IG Jolivet J, Collins JM, et al. Test dose for predicting high-dose methotrexate infusions. Clin Pharmacol Ther. 1983;33(1):44.
- Maiguma T Hayashi Y, Ueshima S, et al. Relationship between oral mucositis and high-dose methotrexate therapy in pediatric acute lymphoblastic leukemia. Int J Clin Pharmacol Ther. 2008;46(11):584–590.
- May J Carson KR, Butler S, et al. High incidence of methotrexate associated renal toxicity in patients with lymphoma: a retrospective analysis. Leuk Lymphoma. 2014;55(6):1345–1349.